Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 468

1.

A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

Connelly PJ, Prentice NP, Cousland G, Bonham J.

Int J Geriatr Psychiatry. 2008 Feb;23(2):155-60.

PMID:
17600848
3.

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M.

Int J Geriatr Psychiatry. 2008 Feb;23(2):161-9.

PMID:
17582225
4.

Folic acid with or without vitamin B12 for cognition and dementia.

Malouf M, Grimley EJ, Areosa SA.

Cochrane Database Syst Rev. 2003;(4):CD004514. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD004514.

PMID:
14584018
5.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
6.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
7.

Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.

Arch Gerontol Geriatr Suppl. 2004;(9):297-307.

PMID:
15207427
8.
9.

Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

Cooke JR, Loredo JS, Liu L, Marler M, Corey-Bloom J, Fiorentino L, Harrison T, Ancoli-Israel S.

Drugs Aging. 2006;23(6):503-11.

PMID:
16872233
10.

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, Schindler R; AWARE Study Group.

CNS Drugs. 2006;20(4):311-25. Erratum in: CNS Drugs. 2006;20(10):866.

PMID:
16599649
11.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
13.

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

Aguglia E, Onor ML, Saina M, Maso E.

Curr Med Res Opin. 2004 Nov;20(11):1747-52.

PMID:
15537474
14.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
15.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
16.

A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.

Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):361-8. Epub 2005 May 24.

PMID:
15912389
17.

Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants.

Cornelli U.

Neurodegener Dis. 2010;7(1-3):193-202. doi: 10.1159/000295663. Epub 2010 Mar 12.

PMID:
20224285
18.

Effects of galantamine in patients with mild Alzheimer's disease.

Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S.

Curr Med Res Opin. 2004 Nov;20(11):1815-20.

PMID:
15537482
20.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603

Supplemental Content

Support Center